Traded Apr 1 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Traded Mar 2, 2026 · Filed Mar 5, 2026
Alkermes's CLO, Alkermes, Inc. sold $60K of Alkermes shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$59,576
Shares × reported transaction price
5 days after results of Feb 25, 2026, 64 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.5% | −2.2% | −0.3% |
| 30 days | +20.2% | −3.3% | +23.5% |
| 90 days | +50.8% | +10.7% | +40.1% |
| 180 days | +66.5% | +11.8% | +54.7% |
Past results only. Not a forecast.
Traded Apr 1 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold ~$320K of Alkermes plc
Scheduled in advanceTraded Apr 1 · filed the same day
Derivative exercise or conversion — not an open-market buy.